New Research Advances Understanding of Liver Diseases at the International Liver Congress (ILC)

April 19, 2017 | By: Rose Christian, M.D., Development Lead, Fibrosis and Ian Waxman, M.D., Development Lead, Gastrointestinal Cancers

A

t Bristol-Myers Squibb, our mission is to deliver transformational medicines to patients with the most serious medical conditions in areas of high unmet need, including those with advanced liver diseases. Members of our teams are off to Amsterdam this month to attend The International Liver Congress™ 2017 (ILC), held by the European Association for the Study of the Liver (EASL). Having made significant contributions to the treatment of chronic viral hepatitis, Bristol-Myers Squibb has a history of research in liver disease, and we continue to leverage that expertise today in our R&D programs. 

Ian Waxman, M.D. and Rose Christian, M.D.,

Ian Waxman, M.D., Development Lead, Gastrointestinal Cancers and Rose Christian, M.D., Development Lead, Fibrosis

At ILC, Bristol-Myers Squibb will present new Phase 2 data on BMS-986036, an investigational compound for non-alcoholic steatohepatitis, or NASH. NASH is a condition marked by excess fat in the liver, which can lead to complications including scarring, cirrhosis, liver failure, liver transplant, or cancer. Currently, the condition is severely underdiagnosed and there are no approved treatments for NASH, which is expected to become one of the leading causes of liver transplantation in the coming years. With a growing worldwide prevalence, the need for a better way to diagnose and treat NASH across the various stages of disease is very high. Read more about NASH.

We will also share an update on our research in hepatocellular carcinoma (HCC), the most common type of liver cancer, and the second most common cause of cancer-related deaths worldwide. More than 700,000 people around the world are diagnosed with HCC each year. The majority of these cases are caused by hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, making HBV/HCV the most common risk factor for liver cancer. Additionally, evidence suggests that the progression of NASH can also cause the disease. HCC is often diagnosed in the advanced stage, where a significant unmet need exists. Read more about HCC.

 

NASH, which is expected to become one of the leading causes of liver transplantation in the coming years.

Finally, chronic viral hepatitis continues to be a significant health issue in many areas of the world and we continue to strive to ensure that patients who need treatment options have access to our medicines.  Read more about our developing world strategy.

We continue to work toward our goal of delivering new options to patients living with these conditions and we look forward to joining the research and advocacy community at ILC.